Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Adhesive Capsulitis
NCT06976671Phase 2Recruiting
- Sponsor
- Macquarie University
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in adhesive capsulitis (AC), sponsored by Macquarie University. Primary endpoints: Safety of bevacizumab at 52 weeks and Maximum Tolerated Dose at 1 week. Started Sep 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
adhesive capsulitis (AC)
Beyond the preview
Go deeper on NCT06976671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976671.